Bosentan Therapy for Pulmonary Arterial Hypertension
Why the study?
Does oral bosentan improve outcomes in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support bosentan 125 mg twice daily in PAH; leaves open confirmation from randomized trials.
Structured PICO
Does oral bosentan improve outcomes in patients with pulmonary arterial hypertension?
P
Population
Patients with pulmonary arterial hypertension
I
Intervention
Oral bosentan 125 mg twice daily
Oral bosentan at 125 mg twice daily is an effective and well-tolerated therapy for pulmonary arterial hypertension.
Cite This Study
Rubin et al. (2002) studied this question.